Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session: Breast cancer, metastatic

215MO - ICON – a randomized phase IIb study evaluating chemotherapy combined with ipilimumab and nivolumab in metastatic hormone receptor-positive breast cancer


10 Sep 2022


Mini Oral session: Breast cancer, metastatic


Clinical Research;  Immunotherapy

Tumour Site

Breast Cancer


Jon Amund Kyte


Annals of Oncology (2022) 33 (suppl_7): S88-S121. 10.1016/annonc/annonc1040


J.A. Kyte1, N.K. Andresen1, C. Quaghebeur2, B. Gilje3, B. Boge4, A. Gombos5, A. Røssevold1, R.M.R. Mathiesen6, E. Borgen7, R.S. Falk8, L. Julsrud9, H.G. Russnes10, O.C. Lingjærde11, B. Naume12

Author affiliations

  • 1 Clinical Cancer Research Department And Department Of Cancer Immunology, Oslo University Hospital - The Norwegian Radium Hospital, 0424 - Oslo/NO
  • 2 Oncology, CHR - Centre Hospitalier Régional de Namur, 5000 - Namur/BE
  • 3 Oncology, Stavanger University Hospital - Helse Stavanger HF, 4011 - Stavanger/NO
  • 4 Oncology, Sørlandet Hospital HF, Kristiansand/NO
  • 5 Oncology, Institute Jules Bordet, 1000 - Brussels/BE
  • 6 Dept Of Oncology, Oslo University Hospital, Ulleval, 0450 - Oslo/NO
  • 7 Pathology, Oslo University Hospital, Oslo/NO
  • 8 Biostatistics And Epidemiology, Oslo University Hospital - Rikshospitalet, 0424 - Oslo/NO
  • 9 Radiology And Nuclear Medicine, Oslo University Hospital, Oslo/NO
  • 10 Pathology And Cancer Genetics, Oslo University Hospital - Radiumhospitalet, 0424 - Oslo/NO
  • 11 Cancer Genetics, Oslo University Hospital, Oslo/NO
  • 12 Department Of Oncology, Oslo University Hospital - The Norwegian Radium Hospital, 0424 - Oslo/NO


Login to access the resources on OncologyPRO.

Abstract 215MO


Immune checkpoint inhibitors have not been extensively explored in estrogen receptor-positive breast cancer (ER+ BC). This BC entity is considered to be immunologically “cold”. Therefore, we tested nivolumab (nivo; anti-PD1) and ipilimumab (ipi; anti-CTLA-4) in combination with anthracyclines and low-dose cyclophosphamide, which are reported to provoke immunogenic cell death and to counter immunosuppressive cells.


The trial enrolled patients with ER+ HER-2- metastatic BC and maximum one previous line of chemotherapy after metastasis. Patients were randomized 2:3 into two arms (A:B). Arm A patients received only chemotherapy, i.e. pegylated liposomal doxorubicin (PLD; 20mg/m2 every 2nd week) + cyclophosphamide (cyclo; 50mg/day, 2/4 weeks). Arm B patients received PLD + cyclo + ipi (1mg/kg every 6th week) + nivo (240mg every 2nd week). Descriptive assessments of safety and progression-free survival (PFS) were the primary endpoints. Secondary endpoints included overall survival (OS), objective response rate (ORR), clinical benefit rate (CBR) and biomarkers (PD-L1, immune gene expression, mutation burden). Hazard ratios (HR) are presented with confidence intervals (CI).


82 patients were randomized to arm A (n=33) or arm B (n=49). 46% had not received previous chemotherapy in the metastatic setting. Serious adverse events occurred in 63% of the patients in arm B, versus 39% in arm A. The most common immune related adverse events in arm B were hypothyroidism (45%), hyperthyroidism (22%), hypophysitis (10%) and pneumonitis (8%). Median PFS was 5.1 months in arm B versus 3.7 months in arm A; PFS HR [95% CI] 0.94 [0.59-1.5]. Median OS was 20.9 months versus 19.9 months in arm B and arm A, respectively; OS HR 1.13 [0.65-1.98]. ORR was 32% in arm B versus 29% in arm A. CBR was 55% in arm B versus 48% in arm A. Biomarker analyses and assessments of immunological changes during therapy are ongoing.


The concomitant addition of ipi/nivo to chemotherapy did not show any clear benefit. Patients receiving ipi/nivo had more adverse events, but the toxicity was manageable. Biomarker analyses will be important to determine if further studies on selected subgroups are warranted.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

Oslo University Hospital.


Norwegian Health Region South-East, Bristol Myers Squibb.


J.A. Kyte: Other, Institutional, Research Grant: Bristol Myers Squibb, Roche. B. Gilje: Financial Interests, Personal and Institutional, Advisory Board: Daiichi Sankyo, Novartis, Eli Lilly. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.